Pharma news

Reset all filters
Geography
Company
Refine search
European Parliament backs EMA move, with conditions
Pharma
European Parliament has approved the relocation of the European Medicines Agency from London to Amsterdam.   19 March 2018
Four arrested over fake dietary supplements
Americas
Four people have been arrested and charged with trafficking in counterfeit goods, after an investigation found that they had sold fake dietary supplements for male enhancement or weight loss.   14 March 2018
Allergan and tribe claim PTAB can’t decide on Restasis patents
Americas
Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.   13 March 2018
Pharma
Pharmaceutical company Recordati suffered a setback last week after the EU General Court dismissed its appeal over a trademark registration.   12 March 2018
Americas
Japanese pharmaceutical company Eisai has teamed up with US-based Merck in a deal intended to strengthen the worldwide development and commercialisation of cancer drug Lenvima.   9 March 2018
Pharma
European Council president Donald Tusk appears to have shot down the possibility of the UK remaining part of some EU agencies, including the European Medicines Agency (EMA), after Brexit.   8 March 2018
Pharma
The German Federal Patent Court has set aside a decision by the German Patent and Trade Mark Office to reject a supplementary protection certificatesupplementary protection certificate that GSK Biologicals had applied for, in a decision of “fundamental importance”.   8 March 2018
Americas
The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.   8 March 2018
Americas
AstraZeneca’s research development arm MedImmune has revealed plans to spin out six molecules into an independent biotech company.   6 March 2018
Americas
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.   6 March 2018